Prognostic factor | Patients (n = 14) | Univariate analysis | ||
---|---|---|---|---|
HR | 95% CI | P-value | ||
Tumor size of primary tumora | ||||
T1 and T2 | 12 | |||
T3 and T4 | 2 | 2.455 | 0.472–12.778 | 0.286 |
Clinical LN status at diagnosis | ||||
Negative | 6 | |||
Positive | 8 | 11.43 | 1.402–93.175 | 0.023 |
Pathological LN status of primary tumor | ||||
Negative | 7 | |||
Positive | 7 | 6.637 | 1.358–32.438 | 0.019 |
Primary ER status | ||||
Negative | 5 | |||
Positive | 9 | 1.031 | 0.271–3.929 | 0.964 |
Primary HER2 status | ||||
Negative | 9 | |||
Positive | 5 | 1.063 | 0.667–1.695 | 1.063 |
Type of surgery | ||||
Mastectomy | 10 | |||
Partial mastectomy | 4 | 0.570 | 0.116–2.792 | 0.570 |
Perioperative Chemotherapy | ||||
Yes | 10 | 1.724 | 0.356–8.355 | 0.499 |
No | 4 | |||
Post mastectomy radiation therapy | ||||
Yes | 4 | |||
No | 10 | 5.435 | 1.202–24.581 | 0.028 |
Disease free interval | ||||
≤ 1 year | 4 | |||
> 1 year | 10 | 0.396 | 0.95–1.638 | 0.201 |
Number of metastatic lymph nodes at recurrence | ||||
≤ 2 lymph nodes | 8 | |||
≥ 3 lymph nodes | 6 | 0.675 | 0.168–2.714 | 0.580 |
Number of regions of metastatic lymph nodes at recurrence | ||||
1 | 12 | |||
2 | 2 | 1.123 | 0.137–9.231 | 0.914 |
Hormone therapy after recurrence | ||||
Yes | 4 | 1.084 | 0.257–4.567 | 0.913 |
No | 10 | |||
Chemotherapy after recurrence | ||||
Yes | 9 | 0.422 | 0.1112–1.587 | 0.202 |
No | 5 | |||
Operation after recurrence | ||||
Yes | 2 | |||
No | 12 | 0.515 | 0.064–4.155 | 0.534 |
Radiation therapy after recurrence | ||||
Yes | 8 | 0.900 | 0.238–3.408 | 0.877 |
No | 6 |